Barrett's Esophagus with Dysplasia Market

• The market for Barrett's esophagus with dysplasia is expected to maintain a steady Compound Annual Growth Rate (CAGR) during the forecast period [2024-2034]. This increase in market revenue is primarily driven by advancements in diagnostic methods, increased awareness of the condition, and a rising number of reported cases.
• Barrett’s esophagus with dysplasia cases are increasing due to an increase in cases of Barrett’s esophagus which is associated with several risk factors such as social drinking, smoking, and hiatal hernia among others.
• Despite the well-established benefits of currently approved proton pump inhibitors (PPIs) in the treatment of dysplastic Barrett’s esophagus, the unmet needs are still present and although often frustrating, they challenge clinicians.
• The unmet needs revolve around the inability to achieve full control of acid secretion through oral proton pump inhibitor (PPI) administration in managing patients experiencing symptoms.
• The existing market for Barrett's esophagus with dysplasia is distinguished by limited competition owing to the absence of FDA-approved treatments and the limited availability of therapeutic options.
• In order to enhance the quality of life for these patients and reduce the necessity for numerous medical consultations and unnecessary investigations, the market is eagerly anticipating new treatments that go beyond the current regimen.
• To drive the Barrett’s esophagus with dysplasia market in future years, a very few companies including Trio Medicines, among others are developing their assets for the treatment of Barrett’s esophagus with dysplasia. With the expected approval of these therapies during the forecast period [2024–2034], the overall therapeutic market of Barrett’s esophagus with dysplasia is likely to witness a rise at a significant CAGR.

DelveInsight’s comprehensive report titled “Barrett’s Esophagus with Dysplasia Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of Barrett’s esophagus with dysplasia. The report presents historical and projected epidemiological data covering Total Prevalent Cases of Barrett’s Esophagus and Diagnosed Prevalent Cases of Barrett’s Esophagus with Dysplasia further segmented by Severity. In addition to epidemiology, the market report encompasses various aspects of the patient population.

These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in Barrett’s esophagus with dysplasia. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Barrett’s Esophagus with Dysplasia Overview

Barrett's Esophagus is a complication of gastroesophageal reflux disease (GERD). GERD is a condition in which the stomach contents, including acid, reflux into the esophagus. People with Barrett's esophagus may develop a rare cancer called esophageal adenocarcinoma.

Barrett's esophagus is a pre-malignant condition characterized by the conversion of the normal esophageal squamous epithelium into metaplastic columnar epithelium. The stomach lining is mucinous columnar epithelium made to withstand the acidic environment required for digestion; however, the esophagus is lined by squamous epithelium. As a response to the acidic irritant, the squamous epithelium becomes inflamed. Continued exposure to acids leads to persistent inflammation and a columnar metaplasia reaction with the eventual development of an intestinal-type phenotype characterized by the presence of goblet cells.

Over time, the gland cells in Barrett’s esophagus can become increasingly abnormal, a condition known as dysplasia. Dysplasia is considered a pre-cancerous stage. While the cells are abnormal, they are unable to spread to other parts of the body.

Dysplasia is characterized by the presence of abnormal epithelium confined within the basement membrane of the gland where it originates. Unlike dysplastic lesions associated with inflammatory bowel disease, most cases of Barrett-related dysplasia do not closely resemble colonic adenomas. Instead, typical Barrett-related dysplasia often occurs in glands that maintain their normal structure and frequently lack nuclear stratification.

Dysplasia in Barrett’s Esophagus can be categorized as either low-grade or high-grade depending on the extent of the abnormality observed.

Low-grade dysplasia indicates that some of the cells appear abnormal. While these cells may resemble cancer cells in some aspects, they are unable to metastasize to other parts of the body. This condition represents a very early stage of pre-cancer in the esophagus. Individuals with Barrett’s esophagus and low-grade dysplasia do have a heightened risk of esophageal cancer, although most individuals with this condition do not progress to develop cancer.

High-grade dysplasia indicates that the cells in the region of Barrett’s esophagus appear highly abnormal. This represents a more advanced stage of pre-cancer in the esophagus compared to low-grade dysplasia. Individuals with Barrett’s esophagus and high-grade dysplasia have a greater risk of developing esophageal cancer compared to those with low-grade dysplasia.

Barrett's esophagus typically doesn't cause symptoms on its own. However, it can be linked to complications of GERD (gastroesophageal reflux disease), such as heartburn, chest pain, upper abdominal pain, and difficulty in swallowing food, dry cough or frequent throat clearing, regurgitation of sour-tasting fluid into the mouth, frequent burping or belching, among other symptoms.

Barrett’s Esophagus with Dysplasia Diagnosis and Treatment Algorithm

The diagnosis of Barrett's esophagus involves an upper gastrointestinal (GI) endoscopy and a biopsy. Patients diagnosed typically show gastroesophageal reflux disease symptoms with no distinct clinical or radiologic manifestations of Barrett's esophagus dysplasia. The gold standard for detecting dysplasia in the surveillance of BE involves obtaining 4-quadrant biopsies following the Seattle protocol using white light endoscopy (WLE).

The treatment for Barrett’s esophagus with dysplasia depends on the degree of dysplasia found in the esophageal cells. Chemoprevention with aspirin, other NSAIDs, PPIs, metformin, prokinetic agents, and statins is under study. Endoscopic resection techniques include mucosal resection, submucosal dissection, radiofrequency ablation, and cryotherapy. Radiofrequency ablation has compelling evidence for efficacy and hence is the most commonly used endoscopic resection technique. Long-term PPI therapy and surveillance are recommended after dysplasia ablation.

Barrett’s Esophagus with Dysplasia Epidemiology

The epidemiology section of Barrett’s esophagus with dysplasia market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Barrett’s esophagus with dysplasia. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• During the analysis of Barrett’s esophagus, it was found that the estimated prevalence is approximately 5.6% in the adult population in the US.
• The estimated prevalence of Barrett's esophagus in the general population was found to vary widely, ranging from 0.4% to more than 20%.
• During the analysis, it was found that males are more prevalent in Barrett's esophagus compared to females. Specifically, the prevalence was found to be 53% in males.
• The analysis observed that approximately 11.1% of patients with Barrett's esophagus had high-grade dysplasia.
• In the analysis, it was found that the prevalence of low-grade dysplasia was around 11.4%, while the prevalence of high-grade dysplasia was approximately 4.8% among patients with Barrett's esophagus.
• The epidemiological landscape of Barrett’s esophagus with dysplasia is expected to experience changes during the forecast period (2020-2034).

Barrett’s Esophagus with Dysplasia Market Outlook

The Barrett’s esophagus with dysplasia therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2024–2034].

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, Barrett’s esophagus with dysplasia market in the 7MM is expected to change significantly during the study period 2020–2034.

Barrett’s Esophagus with Dysplasia Drug Chapters

Emerging Barrett’s Esophagus with Dysplasia Drugs

The Barrett’s esophagus with dysplasia market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Trio Medicines, among others have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

Ceclazepide: Trio Medicines

Ceclazepide, also known as TR2-A, is a prodrug and a novel, potent, and highly selective gastrin/CCK2 receptor antagonist indicated for the treatment of Barrett's esophagus. The body efficiently converts TR2-A to the active molecule TR2 in the bloodstream. The patent application for ceclazepide was recently approved in Europe and the US. Currently, the drug is in the preclinical phase of clinical development, with no updates from the company since 2021.

Note: Detailed emerging therapies assessment will be provided in the final report...

Barrett’s Esophagus with Dysplasia Market Segmentation

DelveInsight’s ‘Barrett’s Esophagus with Dysplasia – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future Barrett’s esophagus with dysplasia market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Barrett’s Esophagus with Dysplasia Market Size by Countries

The Barrett’s esophagus with dysplasia market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) Barrett’s esophagus with dysplasia market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Barrett’s Esophagus with Dysplasia Market Size by Therapies

Barrett’s Esophagus with Dysplasia Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034.

Market Share Distribution of Barrett’s esophagus with dysplasia by Therapies in 2034

Note: Detailed market segment assessment will be provided in the final report...

Barrett’s Esophagus with Dysplasia Drugs Uptake

This section focuses on the sales uptake of potential Barrett’s esophagus with dysplasia drugs that have recently been launched or are anticipated to be launched in the Barrett’s esophagus with dysplasia market between 2020 and 2034. It estimates the market penetration of Barrett’s esophagus with dysplasia drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Barrett’s esophagus with dysplasia market.

The emerging Barrett’s esophagus with dysplasia therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Barrett’s esophagus with dysplasia market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Barrett’s esophagus with dysplasia...

Barrett’s Esophagus with Dysplasia Market Access and Reimbursement

DelveInsight’s ‘Barrett’s Esophagus with Dysplasia – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of Barrett’s esophagus with dysplasia.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Barrett’s esophagus with dysplasia market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Barrett’s esophagus with dysplasia domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns for Barrett’s esophagus with dysplasia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and Barrett’s esophagus with dysplasia unmet needs.

Barrett’s Esophagus with Dysplasia: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Creighton University Medical Center, American College of Gastroenterology, Division of Gastroenterology, Department of Medicine in the US, Division of Gastroenterology and Hepatology, University of Utah School of Medicine in the US, among others.

“Barrett's esophagus presents a significant clinical challenge due to its association with esophageal cancer. Early detection through regular endoscopic surveillance is paramount in high-risk patients with chronic acid reflux.”

“The unmet need in Barrett's esophagus lies in the development of targeted therapies that can halt or reverse the progression of precancerous lesions. While current treatments focus on symptom management and surveillance, there's a clear gap in our ability to intervene at an early stage to prevent esophageal adenocarcinoma.”

Note: Detailed assessment of KOL Views will be provided in the full report on Barrett’s esophagus with dysplasia...

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of Barrett’s esophagus with dysplasia Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Barrett’s Esophagus with Dysplasia Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Barrett’s esophagus with dysplasia. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Barrett’s esophagus with dysplasia therapies.

Barrett’s Esophagus with Dysplasia Report Insights

• Barrett’s Esophagus with Dysplasia Patient Population
• Therapeutic Approaches
• Barrett’s Esophagus with Dysplasia Pipeline Analysis
• Barrett’s Esophagus with Dysplasia Market Size and Trends
• Barrett’s Esophagus with Dysplasia Market Opportunities
• Impact of Upcoming Therapies

Barrett’s Esophagus with Dysplasia Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Barrett’s Esophagus with Dysplasia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Barrett’s Esophagus with Dysplasia Market

Barrett’s Esophagus with Dysplasia Drugs Uptake

• Barrett’s Esophagus with Dysplasia Report Assessment
• Barrett’s Esophagus with Dysplasia Current Treatment Practices
• Unmet Needs
• Barrett’s Esophagus with Dysplasia Pipeline Product Profiles
• Barrett’s Esophagus with Dysplasia Market Attractiveness

Key Questions

• How common is Barrett’s Esophagus with Dysplasia?
• What are the key findings of Barrett’s Esophagus with Dysplasia epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for Barrett’s Esophagus with Dysplasia?
• What is the disease risk, burden, and unmet needs of Barrett’s Esophagus with Dysplasia?
• At what CAGR is the Barrett’s Esophagus with Dysplasia market and its epidemiology is expected to grow in the 7MM during the forecast period (2024–2034)?
• How would the unmet needs impact Barrett’s Esophagus with Dysplasia market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of Barrett’s Esophagus with Dysplasia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024–2034)?
• How many companies are currently developing therapies for the treatment of Barrett’s Esophagus with Dysplasia?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving Barrett’s Esophagus with Dysplasia Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.